Peter Svennilson Elected to RAPT Therapeutics Board of Directors
June 18 2020 - 4:05PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced the election of Peter
Svennilson, Managing Partner of The Column Group, to its Board of
Directors. Mr. Svennilson will replace David Goeddel, Ph.D., who
did not stand for reelection to RAPT’s Board of Directors due to
other responsibilities, but will remain a member of RAPT’s
Scientific Advisory Board (SAB).
“Peter has been integrally involved with RAPT over the course of
the last several years, helping to steer our strategic direction
and expanding our network within the industry, and we welcome his
consistent counsel as an active Board member moving forward,” said
Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.
“On behalf of the Board and the entire Company, I’d like to thank
David for his guidance and strategic direction, as well as his
mentorship over the course of the last five years. We very much
appreciate his contributions and are thrilled he will continue his
involvement with RAPT through our SAB.”
Mr. Svennilson was elected to the Board of Directors at RAPT’s
Annual Stockholder Meeting on Thursday, June 18, 2020. He is
currently Managing Partner and Founder of The Column Group, a San
Francisco-based biotechnology venture capital firm. Prior to
founding The Column Group, Mr. Svennilson founded Three Crowns
Capital, where he served as Managing Partner, and before that was
Associate Managing Director in charge of European Investment
Banking Origination at Nomura Securities in London. In addition to
serving on RAPT’s Board of Directors, Mr. Svennilson serves on the
Boards of Directors of ORIC Pharmaceuticals, Inc., Ribon
Therapeutics, Circle Pharma and Revolution Medicines, Inc.
Previously, he served as Chairman of the Board of Directors of
Seragon Pharmaceuticals, Inc. and Aragon Pharmaceuticals, Inc. Mr.
Svennilson also served as a member of the Boards of Directors of
Gritstone Oncology, Inc., Constellation Pharmaceuticals, Inc., NGM
Biopharmaceuticals, Inc., PTC Therapeutics, Inc., Immune Design,
Rosetta Inpharmatics LLC, ChemoCentryx, Inc. and Somalogic, Inc.
and as Board Observer of Arcus Biosciences. Mr. Svennilson is
currently a Trustee for The Institute for Advanced Study in
Princeton, New Jersey. He received his M.B.A. from the Stockholm
School of Economics and Finance.
“I’m delighted to join the Board of Directors at this exciting
time in RAPT’s history,” commented Mr. Svennilson. “With
proof-of-concept data expected for both FLX475 and RPT193 this year
and a robust early-stage portfolio of small molecules advancing
through development, the Company is poised for growth. I look
forward to working with the experienced management team to support
the Company’s evolution and advancement across a number of segments
and therapeutic areas within our industry.”
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets, including hematopoietic progenitor kinase 1 (HPK1) and
general control nonderepressible 2 (GCN2), that are in the
discovery stage of development.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements relate to future events and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different
from any future performances or achievements expressed or implied
by the forward-looking statements. Each of these statements is
based only on current information, assumptions and expectations
that are inherently subject to change and involve a number of risks
and uncertainties. Forward-looking statements include, but are not
limited to, statements about clinical development progress and the
timing of results from clinical trials of FLX475 and RPT193.
Detailed information regarding risk factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in RAPT’s Form
10-Q filed with the Securities and Exchange Commission on May 14,
2020 and subsequent filings made by RAPT with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. RAPT disclaims any obligation to update these
forward-looking statements.
Media Contact: Angela Bitting media@rapt.com (925) 202-6211
Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024